Novartis AG Common Stock (NY:NVS)

The Silicon Laureates: How the 2024 Nobel Prizes Rewrote the Rules of Scientific Discovery

Topics ETFs Economy

January 26, 2026

The year 2024 marked a historic inflection point in the history of science, as the Royal Swedish Academy of Sciences awarded Nobel Prizes in both Physics and Chemistry to pioneers of artificial...

Novartis (NVS) is trading at new all-time highs on Monday. Shares are up nearly 50% over the past 52 weeks. NVS maintains a 100% “Buy” technical opinion from Barchart. Novartis has benefitted in recent...

Topics Artificial Intelligence

Is This Pharmaceutical Giant a Winning Tariff-Proof Stock to Buy for 2026?

January 26, 2026

Via Barchart.com

Topics World Trade

Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock Backed by Strong Fundamentals ↗

January 23, 2026

Via Chartmill

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case ↗

January 20, 2026

Via Chartmill

International ETFs: SPDW and SCHF Both Offer Low Cost International Exposure ↗

January 24, 2026

Explore how these two leading ETFs differ on risk, yield, and portfolio makeup—key factors for building a balanced global strategy.

These two ETFs will help take your portfolio around the world, with each fund making longer pit stops in certain continents.

Topics ETFs

VWO vs. SPDW: How Does a Emerging Markets ETF Fair Against a Developed World Fund? ↗

January 24, 2026

The Software Surge: How 2024’s $25.7 Billion M&A Explosion in Diagnostics Redefined Healthcare

Topics ETFs

January 23, 2026

The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence...

Novartis CEO says US manufacturing investments and a federal agreement could limit tariff exposure as proposed Trump levies target Europe.

Topics Artificial Intelligence Economy

Novartis Positions US Strategy As Defense Against Rising Trade Levies ↗

January 23, 2026

Via Benzinga

Topics Government World Trade

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...

Palantir's top and bottom lines are both moving in the right direction. Enough investors just need to notice it again.

Topics Artificial Intelligence ETFs Initial Public Offering

The Software Stock That Could Be 2026's Biggest Surprise ↗

January 22, 2026

In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion....

Topics Artificial Intelligence

GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics

January 20, 2026

Silicon Meets Science: NVIDIA and Eli Lilly Launch $1 Billion AI Lab to Engineer the Future of Medicine

Topics Intellectual Property

January 19, 2026

In a move that signals a paradigm shift for the pharmaceutical industry, NVIDIA (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) have announced the launch of a $1 billion joint AI co-innovation...

Explore how differences in regional focus, sector exposure, and portfolio makeup may impact your ETF investing strategy.

Topics Artificial Intelligence

International Exposure: SPDW's Lower Costs vs. URTH's U.S. Giants ↗

January 17, 2026

In a milestone that many researchers are calling the "biological equivalent of the moon landing," AlphaFold 3 has officially moved structural biology into a new era of predictive precision. Developed...

Topics ETFs

The Atomic Revolution: How AlphaFold 3 is Redefining the Future of Medicine

January 16, 2026

NVS Stock Rises After FDA Grants Breakthrough Therapy Designation For Autoimmune Disorder Treatment ↗

Topics Artificial Intelligence

January 16, 2026

Novartis looks to submit data from its many trials of Ianalumab with health authorities starting in early 2026 for potential approval.

Via Stocktwits

The Atomic Revolution: How AlphaFold 3’s Open-Source Pivot Has Redefined Global Drug Discovery in 2026

January 15, 2026

The decision by Google DeepMind and its commercial sister company, Isomorphic Labs, to fully open-source AlphaFold 3 (AF3) has emerged as a watershed moment for the life sciences. As of January 2026,...

The Silicon Laureates: How the 2024 Nobel Prizes Cemented AI as the New Language of Science

Topics Artificial Intelligence Derivatives Economy

January 15, 2026

The announcement of the 2024 Nobel Prizes in Physics and Chemistry sent a shockwave through the global scientific community, signaling a definitive end to the "AI Winter" and the beginning of what...

The iShares Core MSCI EAFE ETF and the SPDR Portfolio Developed World ex‑US ETF may look similar on paper, but each offers a distinct approach to owning international stocks outside the U.S.

Topics Artificial Intelligence

IEFA vs. SPDW: Broad International Exposure With Different Portfolio Designs ↗

January 14, 2026

The Silicon Laureates: How 2024’s ‘Nobel Prize Moment’ Rewrote the Laws of Scientific Discovery

Topics ETFs

January 14, 2026

The history of science is often measured in centuries, yet in October 2024, the timeline of human achievement underwent a tectonic shift that is only now being fully understood in early 2026. By...

As of January 2026, the landscape of biological research has been irrevocably altered by the maturation of AlphaFold 3, the latest generative AI milestone from Alphabet Inc. (NASDAQ: GOOGL). Developed...

Topics Artificial Intelligence Electric Vehicles

The Digital Microscope: How AlphaFold 3 is Decoding the Molecular Language of Life

January 14, 2026

SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout ↗

Topics Artificial Intelligence Bonds

January 14, 2026

The IMPACT-AML program will conduct a European clinical study evaluating SLS009 and provide SELLAS access to multiple clinical sites and a broader patient population.

Via Stocktwits

Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation

January 14, 2026

Date: January 14, 2026 Viatris Inc. (NASDAQ: VTRS) stands at a critical crossroads in early 2026. After years of functioning as a complex, debt-laden conglomerate formed from the massive merger of...

Via Finterra

Topics Earnings Economy Intellectual Property

Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS

January 13, 2026

On January 13, 2026, Travere Therapeutics (NASDAQ: TVTX) faced a sharp reversal of fortune as the U.S. Food and Drug Administration (FDA) announced a three-month extension for its review of Filspari...

Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...

Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance

January 13, 2026

Via PredictStreet

Topics Economy Intellectual Property

The Evolution of a Giant: A Deep Dive into the ‘New’ Johnson & Johnson (JNJ) in 2026

January 13, 2026

As of January 13, 2026, Johnson & Johnson (NYSE: JNJ) stands at a pivotal juncture in its nearly 140-year history. Once a sprawling conglomerate synonymous with baby shampoo and Band-Aids, the "New...

Via PredictStreet

Topics Artificial Intelligence Bankruptcy Economy

Why Tempus AI Stock Rose Today ↗

January 12, 2026

The data provider's artificial intelligence-driven solutions are accelerating drug discovery.

Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution

Topics Artificial Intelligence

January 12, 2026

In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom"...

All three offer much more than a regular payout.

Topics Artificial Intelligence

Is Novartis AG Gaining or Losing Market Support? ↗

January 12, 2026

Via Benzinga

3 Dividend Stocks to Buy in 2026 and Hold Forever ↗

January 11, 2026